<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01499108</url>
  </required_header>
  <id_info>
    <org_study_id>2011-005344-95</org_study_id>
    <nct_id>NCT01499108</nct_id>
  </id_info>
  <brief_title>Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 Diabetes</brief_title>
  <acronym>Liratime</acronym>
  <official_title>Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter Rossing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Steno Diabetes Center Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Preclinical blood pressure (BP) data from studies of hypoglycemic effects of&#xD;
      liraglutide treatment (the LEAD program), revealed a significant antihypertensive potential.&#xD;
      The time course and the mechanism behind this effect are unknown.&#xD;
&#xD;
      Objectives: To evaluate the time course of the antihypertensive effect of liraglutide&#xD;
      treatment in patients with type 2 diabetes&#xD;
&#xD;
      Design: Open-label study with intervention and subsequent washout period&#xD;
&#xD;
      Patient Population: 35 hypertensive (SBP ≥130 mm Hg and DBP ≥80 mmHg) patients with type 2&#xD;
      diabetes.&#xD;
&#xD;
      Intervention: All patients will be treated with liraglutide 0.6 mg once daily for 7 days and&#xD;
      will then be titrated to 1.2 mg once daily for 14 days and then titrated to 1.8 mg once daily&#xD;
      for 4 weeks. This is followed by a washout period of 3 weeks without liraglutide treatment.&#xD;
&#xD;
      Endpoints: 24-hour blood pressure, natriuresis, extra cellular volume (ECV&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypotheses Primary hypothesis • Liraglutide treatment causes a reduction in 24h BP&#xD;
&#xD;
      Secondary hypothesis:&#xD;
&#xD;
        -  The effect on BP may be mediated by an increase in natriuresis, thereby affecting ECV&#xD;
&#xD;
        -  The effect on BP may be mediated by a decrease in arterial stiffness and central aortic&#xD;
           pressure&#xD;
&#xD;
      Purpose Primary purpose&#xD;
&#xD;
      • To assess how quickly the antihypertensive effect of liraglutide treatment set in after&#xD;
      initiation in patients with type 2 diabetes&#xD;
&#xD;
      Secondary objectives&#xD;
&#xD;
        -  To measure the effect of liraglutide treatment on natriuresis.&#xD;
&#xD;
        -  To measure the effect of liraglutide treatment on ECV&#xD;
&#xD;
        -  To measure the effect of liraglutide treatment on arterial stiffness&#xD;
&#xD;
        -  To measure weight change after initiation of liraglutide treatment&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ambulatory blood pressure</measure>
    <time_frame>50 days</time_frame>
    <description>Change in 24h BP from day 1 to day 49 (baseline to end of treatment) and time to statistically significant change in BP 24h after initiation of or increased dose of liraglutide</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in ECV</measure>
    <time_frame>50 days</time_frame>
    <description>Changes in ECV (measured by GFR), urinary sodium, weight, arterial stiffness and daily home-BP, from day 1 to day 49 (baseline to end of treatment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Washout analysis</measure>
    <time_frame>21</time_frame>
    <description>Change in 24h BP, ECV, weight, arterial stiffness from day 49 to day 70th</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Liraglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single-group study were participants recieve Liraglutide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>Subcutaneous injection of liraglutide at doses of 0.6, 1.2, and 1.8 mg once daily during the 49 days duration of the study</description>
    <arm_group_label>Liraglutide</arm_group_label>
    <other_name>Victoza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must give written informed consent before participation. Patient information and&#xD;
             consent form must be approved by the Danish Medicines Agency and the Regional&#xD;
             Scientific Ethical Committee&#xD;
&#xD;
          2. Male or female patients &gt; 18 years with type 2 diabetes (WHO criteria).&#xD;
&#xD;
          3. Patients must be on treatment with metformin. Any form of treatment with SU compounds&#xD;
             will be discontinued and washed out for two weeks prior to the start of study drug.&#xD;
&#xD;
          4. eGFR ≥ 60 ml/min/1.73 m2 (estimated by MDRD formula)&#xD;
&#xD;
          5. Fertile female patients must use chemical, hormonal and mechanical contraceptives or&#xD;
             be in menopause (i.e. must not have had regular menstrual bleeding for at least one&#xD;
             year) or have undergone bilateral oophorectomy or have been surgically sterilized or&#xD;
             hysterectomised at least six months prior to screening&#xD;
&#xD;
          6. Patients must be on antihypertensive treatment or having elevated blood pressure (SBP&#xD;
             ≥130 mm Hg and DBP ≥80 mmHg), lower than 170/105 mm Hg at baseline and the patients&#xD;
             must be stable antihypertensive medication for at least 4 weeks prior to baseline&#xD;
&#xD;
          7. Patients must be on stable hypoglycemic medication for at least two weeks before the&#xD;
             first visit.&#xD;
&#xD;
          8. Must be able to communicate with the investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Ongoing insulin therapy&#xD;
&#xD;
          2. BP &gt; 170/105 mm Hg at baseline&#xD;
&#xD;
          3. Type 1 diabetes mellitus&#xD;
&#xD;
          4. Chronic pancreatitis / previous acute pancreatitis&#xD;
&#xD;
          5. Known or suspected hypersensitivity to trial product(s) or related products.&#xD;
&#xD;
          6. Treatment with oral glucocorticoids, calcineurin inhibitors, or dipeptidyl peptidase 4&#xD;
             (DPP4) inhibitors which in the Investigator's opinion could interfere with glucose or&#xD;
             lipid metabolism 90 days prior to screening&#xD;
&#xD;
          7. Cancer (except basal cell skin cancer or squamous cell skin cancer) or any other&#xD;
             clinically significant disorder, except for conditions associated with type 2 diabetes&#xD;
             history, which in the investigators opinion could interfere with the results of the&#xD;
             trial&#xD;
&#xD;
          8. Inflammatory bowel disease&#xD;
&#xD;
          9. Cardiac disease defined as: Decompensated heart failure (NYHA class III-IV) and/or&#xD;
             diagnosis of unstable angina pectoris and/or myocardial infarction within the last 6&#xD;
             months&#xD;
&#xD;
         10. Previous bowel resection&#xD;
&#xD;
         11. Body mass index &lt;18.5 kg/m2&#xD;
&#xD;
         12. Females of childbearing potential who are pregnant, breast-feeding, intend to become&#xD;
             pregnant or are not using adequate contraceptive methods&#xD;
&#xD;
         13. Clinical signs of diabetic gastroparesis&#xD;
&#xD;
         14. Impaired liver function (transaminases &gt; two times upper reference levels)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Rossing, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Steno Diabetes Centes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Steno Diabetes Center</name>
      <address>
        <city>Gentofte</city>
        <zip>2820</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>December 12, 2011</study_first_submitted>
  <study_first_submitted_qc>December 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 26, 2011</study_first_posted>
  <last_update_submitted>January 30, 2015</last_update_submitted>
  <last_update_submitted_qc>January 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Steno Diabetes Center Copenhagen</investigator_affiliation>
    <investigator_full_name>Peter Rossing</investigator_full_name>
    <investigator_title>Director of Research, Chief Physician, DMSc</investigator_title>
  </responsible_party>
  <keyword>type 2 diabetes</keyword>
  <keyword>hypertension</keyword>
  <keyword>liraglutide</keyword>
  <keyword>kidney function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

